Conference Correspondent

Conference Correspondent — December 13, 2021
Myelofibrosis patients typically prepare for allo-SCT by suspending ruxolitinib therapy, which subsequently results in worsening disease manifestations. Continuation of ruxolitinib therapy in an off-label approach offers a safer option according to interim phase 2 data.
Read Article

Conference Correspondent — December 13, 2021
Myelofibrosis patients refractory to JAK inhibitor therapy typically have poor prognosis. Pelabresib demonstrates improvement in clinical outcomes while maintaining an acceptable safety profile in this patient subset.
Read Article

Conference Correspondent — December 13, 2021
Anemia is a common side effect in many patients with myelofibrosis on ruxolitinib therapy. Phase 2 clinical trial data demonstrate mitigation of anemia indices in this patient population by sotatercept.
Read Article

Conference Correspondent — December 13, 2021
Patients with myelofibrosis who are refractory to JAK inhibitors often lack safe and effective treatment options. Selinexor may slow disease progression by reducing growth of malignant myelofibrosis cells.
Read Article

Conference Correspondent — December 13, 2021
Ruxolitinib is an approved therapy for myelofibrosis but some patients experience serious side effects. Fedratinib is an effective therapeutic option for these patients without development of severe adverse events.
Read Article

Conference Correspondent — December 21, 2020
Utilization management tools and prior authorization are associated with delays in care for patients and high costs for physicians. In this session, panelists discuss the impact on cancer care, with an eye toward providing appropriate care while minimizing administrative burden.
Read Article

Conference Correspondent — December 18, 2020
With more than 1.8 million diagnoses of cancer per year in the United States, identifying malignancies at the earliest stage is priority among physicians. In this session, experts discuss the future of early-stage cancer diagnosis and how to improve cancer screenings.
Read Article

Conference Correspondent — December 17, 2020
Oncology nurse and patient navigators are playing an ever-increasing role in supporting patients with cancer and their caregivers. In this session, experts discuss the standardized measures and processes used by oncology nurse and patient navigators.
Read Article

Conference Correspondent — December 16, 2020
In this session, experts discuss the challenges faced at the beginning of the COVID-19 pandemic, how they worked to overcome them, and what lessons they will take with them into the future.
Read Article

Conference Correspondent — December 15, 2020
Specialized oncology pharmacy programs are playing an ever-increasing role in the complex delivery of care. In this session, panelists discuss the obstacles and successes of specialized oncology pharmacy programs.
Read Article

Page 3 of 44